by HealthDay Reporter | Mar 22, 2024
20 percent of patients treated with Breyanzi achieved a complete response. The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for...
by HealthDay Reporter | Mar 20, 2024
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups. Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical...
by HealthDay Reporter | Mar 18, 2024
Incidence of new-onset autoimmune disease higher compared with those with nonfunctioning pituitary adenomas. Patients achieving surgical remission of Cushing disease (CD) have a higher incidence of autoimmune disease compared with those with...
by HealthDay Reporter | Mar 14, 2024
Stratification based on prelymphodepletion C-reactive protein, ferritin can classify patients into high, intermediate, and low risk. For patients with diffuse large B-cell lymphoma (DLBCL), a simple risk stratification can predict outcomes for patients...
by HealthDay Reporter | Mar 12, 2024
Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45 percent. For patients with polycythemia vera, rusfertide treatment reduces the use of phlebotomy and maintains hematocrit of less than 45 percent, according to a study...
